Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CEO Yu-Hsin Lin sold 365 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $180.35, for a total transaction of $65,827.75. Following the completion of the transaction, the chief executive officer owned 170,569 shares in the company, valued at $30,762,119.15. The trade was a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Belite Bio Price Performance

Shares of BLTE opened at $166.26 on Friday. The company has a market capitalization of $6.66 billion, a PE ratio of -65.72 and a beta of -1.22. Belite Bio, Inc. Sponsored ADR has a one year low of $60.00 and a one year high of $200.00. The company’s fifty day moving average price is $152.11 and its 200 day moving average price is $159.84.

Belite Bio (NASDAQ:BLTE) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.26. Analysts anticipate that Belite Bio, Inc. Sponsored ADR will post -3.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on BLTE shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Belite Bio in a research report on Wednesday. Truist Financial set a $217.00 price objective on Belite Bio in a research report on Friday, May 22nd. Mizuho lowered their price objective on shares of Belite Bio from $223.00 to $215.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 26th. Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research report on Friday, May 22nd. Finally, HC Wainwright upped their target price on shares of Belite Bio from $200.00 to $214.00 and gave the company a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Belite Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $204.40.

Hedge Funds Weigh In On Belite Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Darwin Global Management Ltd. bought a new stake in shares of Belite Bio in the 4th quarter worth approximately $486,915,000. RA Capital Management L.P. bought a new stake in shares of Belite Bio during the third quarter valued at approximately $64,750,000. Millennium Management LLC increased its position in shares of Belite Bio by 2,594.6% during the fourth quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock valued at $89,399,000 after purchasing an additional 538,141 shares during the period. RTW Investments LP raised its stake in shares of Belite Bio by 128.9% in the fourth quarter. RTW Investments LP now owns 715,332 shares of the company’s stock valued at $114,425,000 after purchasing an additional 402,832 shares in the last quarter. Finally, Perceptive Advisors LLC raised its stake in shares of Belite Bio by 732.0% in the fourth quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock valued at $66,262,000 after purchasing an additional 364,451 shares in the last quarter. 0.53% of the stock is currently owned by institutional investors.

More Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: The FDA granted priority review to Belite Bio’s tinlarebant New Drug Application for Stargardt disease. The accelerated review sets an expected decision date in February 2027 and follows positive Phase 3 data, potentially shortening the path to commercialization for the company’s lead program. BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
• Positive Sentiment: HC Wainwright raised its price target to $214 from $200 and maintained a Buy rating, signaling continued analyst confidence in tinlarebant’s commercial potential. Belite Bio Price Target Increase
• Positive Sentiment: Second-quarter results exceeded expectations: Belite Bio reported a loss of $0.54 per share versus the consensus estimate of a $0.73 loss. The earnings beat may support sentiment, while management’s corporate update and earnings call provided additional detail on the company’s development programs. Belite Bio Second Quarter 2026 Results
• Neutral Sentiment: Belite Bio remains a clinical-stage biotechnology company, so its valuation and stock performance remain highly dependent on regulatory decisions, clinical execution and the future launch of tinlarebant. Belite Bio Q2 2026 Earnings Call Transcript
• Negative Sentiment: The company continues to report net losses, and analysts expect a full-year loss. With shares trading near their yearly high and at a loss-based price-to-earnings valuation, investors may be taking profits despite the positive FDA and earnings developments.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.